Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of Brensocatib in Healthy Japanese and Caucasian Subjects
NCT05927597Phase 1Completed
- Sponsor
- Insmed Incorporated
- Start
- Jan 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of brensocatib in Non-Cystic Fibrosis Bronchiectasis (NCFB) (5 arms), sponsored by Insmed Incorporated. Primary endpoints: Number of Participants Who Experienced at Least One Adverse Event and Area Under the Plasma Concentration-time Curve of INS1007. Started Jan 2019; status: completed.
02
Drugs
brensocatib
03
Conditions
Non-Cystic Fibrosis Bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT05927597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05927597.